logo
Hasbro executives forecast major profit cuts from Trump tariffs; HQ relocation still TBD

Hasbro executives forecast major profit cuts from Trump tariffs; HQ relocation still TBD

Yahoo25-04-2025

A Mr. Potato Head stands vigil outside Hasbro Inc's headquarters on Newport Avenue in Pawtucket. (Photo by Alexander Castro/Rhode Island Current)
You wouldn't know there was an escalating global trade war by looking at Hasbro Inc.'s first-quarter balance sheet.
But the Pawtucket company's $887 million first-quarter profit doesn't reflect $100 million to $300 million revenue in losses projected for this year as a result of 'reciprocal' tariffs with China and other key international manufacturing hubs for its products.
In an earnings call with investors Thursday morning, hours after Hasbro posted its first-quarter financial report, CEO Chris Cocks detailed the challenges that lie ahead for the toy and game empire under President Donald Trump's current tariffs.
'Even with Hasbro's relative strength and flexibility, logistics are becoming more complex and changes in receivables and shipping dynamics present a challenge,' Cocks said. 'Ultimately, tariffs translate into higher consumer prices, potential job losses as we adjust to absorb increased costs, and reduced profits for our shareholders.'
There were no specifics shared on layoffs or price hikes.
Hasbro has accelerated a shift away from manufacturing in China — where 50% of its toys are made now — and intends to reduce its reliance on Chinese materials and labor to less than 40% of toys by 2026, Gina Goetter, Hasbro chief operating and financial officer, told investors during the call.
Other cost-cutting measures on the horizon include 'source optimization' and 'targeted pricing actions.' Together with potential layoffs and 'prioritizing debt reduction,' Goetter estimated the company would see a net profit loss of $60 million to $180 million this year, mostly reflected in the second half of the year. The estimates are based on an existing 145% U.S. tariff on Chinese goods and a 10% tariff on goods from other countries.
No mention was made of Hasbro's potential relocation to Massachusetts during the earnings call nor in the financial report. But costs associated with swapping its circa 1900 headquarters on Newport Avenue in Pawtucket for a piece of prime Boston-area real estate could be off the table as uncertainty roils the stock and bond markets.
Earlier this month, as Hasbro's stocks plunged to a 52-week low, company executives postponed the headquarters announcement. Originally expected within the first three months of the year, Hasbro now expects to provide 'clarity' on potential moving plans in the summer, Andrea Snyder, a company spokesperson, said previously.
Gov. Dan McKee's office was last in touch with Hasbro via email on April 11, Olivia DaRocha, a spokesperson for McKee's office, said in email Friday afternoon.
Earlier this month, DaRocha said the administration will 'remain engaged' with Hasbro. The publicly traded international company first opened as a family-owned pencil box maker in Providence, and still employs roughly 1,000 workers in Rhode Island.
The economic roller coaster set off by Trump's trade policies has not yet hit home for Hasbro, though. The company saw profits rise 17% compared with a year ago, boosted by a 46% increase in its digital gaming business, featuring Magic: The Gathering and Dungeons & Dragons products.
Its digital gaming segment has been shielded from tariffs because its products are made in the U.S., or are digital, executives said.
The company has also not revised its guidance to investors on its annual performance.
'While we are dealing with a wide range of potential tariff, retailer and consumer outcomes, our games business and our strategic flexibility give us options,' Goetter told investors on the call.
Earnings per diluted share rose to 70 cents per share, up from 42 cents a year ago. Hasbro also saw stocks rebound slightly in the last 30 days. Shares opened at $61.84 Friday morning.
Updated to include a response from Gov. Dan McKee's office.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tesla's (TSLA) Full Self-Driving Could Expand in China Due to New Data Export Rules
Tesla's (TSLA) Full Self-Driving Could Expand in China Due to New Data Export Rules

Business Insider

time35 minutes ago

  • Business Insider

Tesla's (TSLA) Full Self-Driving Could Expand in China Due to New Data Export Rules

China has released draft guidelines that could help EV maker Tesla (TSLA) expand its advanced driver-assistance features in the country, according to a Bloomberg report on Friday. For the first time, Beijing has provided clear rules on how data generated in China, including from driver-assistance systems and product development, can be accessed, used, and exported. This is an important step for companies like Tesla, which need to send data abroad in order to improve their systems. Confident Investing Starts Here: The proposed guidelines were published by China's Ministry of Industry and Information Technology, along with seven other government agencies, and are now open for public comment. The framework covers key types of information, such as autonomous driving algorithms, training images, operational data, and vehicle-to-road perception data. These are all critical for developing and improving advanced driver-assistance technologies like Tesla's Full Self-Driving (FSD) system. Being able to export this data is especially valuable for Tesla because the core team working on FSD is based in the U.S., and having access to real-world data from Chinese roads would help optimize the system's performance in China, the world's largest car market. It's worth noting that, until now, strict data controls have been a barrier for foreign automakers. However, the new guidelines could provide Tesla with a clearer path to making its most advanced driver-assistance features more competitive in China. What Is the Prediction for Tesla Stock? Overall, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 12 Holds, and nine Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average TSLA price target of $285.97 per share implies 12.1% downside risk.

Celtics Shut Down Trade Talk Around Jayson Tatum, Jaylen Brown, And Derrick White
Celtics Shut Down Trade Talk Around Jayson Tatum, Jaylen Brown, And Derrick White

Yahoo

timean hour ago

  • Yahoo

Celtics Shut Down Trade Talk Around Jayson Tatum, Jaylen Brown, And Derrick White

The Boston Celtics have reportedly shut down all trade discussions involving Jayson Tatum, Jaylen Brown, and Derrick White, signaling their intent to maintain the core of their franchise despite a disappointing playoff exit and looming injury concerns. According to NBA insider Brett Siegel: 'Neither Jayson Tatum or Jaylen Brown are on their way out of Boston… League sources are insistent the Celtics have given zero indications that parting ways with Derrick White this summer is a possibility.' Advertisement This stance ends speculation that the franchise could initiate a major roster overhaul following their second-round loss to the New York Knicks. The speculation intensified after news broke that Jayson Tatum may miss the entire 2025-26 season due to an Achilles injury, a catastrophic blow to any contender's title hopes. In the aftermath, even respected voices like Bill Simmons floated the possibility of a fire sale, suggesting blockbuster trades like sending Jaylen Brown and Jrue Holiday to the Houston Rockets. Other rumors linked Brown to the Brooklyn Nets in a stunning scenario, while Kristaps Porzingis reportedly drew interest from the Los Angeles Lakers. Advertisement Meanwhile, Derrick White emerged as a coveted target for teams like the Golden State Warriors, who sought to add perimeter defense and two-way versatility. However, Boston's firm stance on keeping Tatum, Brown, and White indicates a different direction, one of stability amid adversity. The Celtics appear determined to avoid panic moves and instead rely on their core to remain competitive. This decision underscores their confidence in the foundation they've built and perhaps their belief that the window for a title isn't fully closed, even with Tatum's uncertain timeline. That said, with three of their five core players now effectively off the trade market, the attention turns to Jrue Holiday and Kristaps Porzingis. Holiday, who has voiced his desire to return to Boston, may be the odd man out given his contract and the team's desire to manage an impending $500 million payroll. Porzingis, too, could be moved to avoid crossing the second tax apron, especially with growing interest from teams in need of a stretch big with rim protection capabilities. Advertisement While teams like the Warriors were hopeful that a fire sale could give them a shot at acquiring Derrick White, Boston's message is clear: White is part of their long-term vision. His ability to defend at an elite level, initiate offense when needed, and complement stars without demanding high usage makes him a rare and valuable asset in today's NBA. Ultimately, the Celtics' decision to shut down trade talk around Tatum, Brown, and White signals that while the team may need to make tough financial decisions, they are not ready to blow it up. Instead, Boston seems poised to retool around its stars, not rebuild. That may leave players like Holiday and Porzingis on the move, but the Celtics' core, at least for now remains intact. Related: LeBron James Reveals A Major Flaw With The Boston Celtics

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

Yahoo

time3 hours ago

  • Yahoo

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store